Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dermatology

  Free Subscription


Articles published in Cancer Res

Retrieve available abstracts of 118 articles:
HTML format
Text format



Single Articles


    March 2017

  1. Correction: Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
    Cancer Res. 2017;77:1505.
    PubMed     Text format    


    February 2017
  2. STEINBERG SM, Shabaneh T, Zhang P, Martyanov V, et al
    Myeloid cells that impair immunotherapy are restored in melanomas which acquire resistance to BRAF inhibitors.
    Cancer Res. 2017 Feb 15. pii: canres.1755.2016.
    PubMed     Text format     Abstract available


    January 2017
  3. ZHANG T, Xu M, Makowski MM, Lee C, et al
    SDHD promoter mutations ablate GABP transcription factor binding in melanoma.
    Cancer Res. 2017 Jan 20. pii: canres.0919.2016.
    PubMed     Text format     Abstract available


  4. NEUBERT NJ, Tille L, Barras D, Soneson C, et al
    Broad and conserved immune regulation by genetically heterogeneous melanoma cells.
    Cancer Res. 2017 Jan 19. pii: canres.2680.2016.
    PubMed     Text format     Abstract available


    November 2016
  5. JOYCE CE, Yanez AG, Mori A, Yoda A, et al
    Differential regulation of the melanoma proteome by eIF4A1 and eIF4E.
    Cancer Res. 2016 Nov 22. pii: canres.1298.2016.
    PubMed     Text format     Abstract available


  6. AZAN A, Caspers PJ, Bakker Schut TC, Roy S, et al
    A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents.
    Cancer Res. 2016 Nov 11. pii: canres.1733.2016.
    PubMed     Text format     Abstract available


    September 2016
  7. XIA T, Konno H, Barber GN
    Recurrent loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
    Cancer Res. 2016 Sep 28. pii: canres.1404.2016.
    PubMed     Text format     Abstract available


  8. KIM M, Neznanov N, Wilfong CD, Fleyshman DI, et al
    Preclinical validation of a single-treatment infusion modality that can eradicate extremity melanomas.
    Cancer Res. 2016 Sep 28. pii: canres.2764.2015.
    PubMed     Text format     Abstract available


  9. SATOW R, Nakamura T, Kato C, Endo M, et al
    ZIC5 drives melanoma aggressiveness by PDGFD-mediated activation of FAK and STAT3.
    Cancer Res. 2016 Sep 26. pii: canres.0991.2016.
    PubMed     Text format     Abstract available


  10. CLARK CA, Gupta H, Sareddy GR, Pandeswara S, et al
    Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis and autophagy in ovarian cancer and melanoma.
    Cancer Res. 2016 Sep 26. pii: canres.0258.2016.
    PubMed     Text format     Abstract available


  11. KLARQUIST J, Tobin K, Farhangi Oskuei P, Henning SW, et al
    CCL22 DIVERTS T REGULATORY CELLS AND CONTROLS THE GROWTH OF MELANOMA.
    Cancer Res. 2016 Sep 12. pii: canres.0618.2016.
    PubMed     Text format     Abstract available


  12. TAKAHASHI N, Sugaya M, Suga H, Oka T, et al
    Thymic stromal chemokine TSLP acts through Th2 cytokine production to induce cutaneous T cell lymphoma.
    Cancer Res. 2016 Sep 6. pii: canres.0992.2016.
    PubMed     Text format     Abstract available


    August 2016
  13. TEH JL, Purwin TJ, Greenawalt EJ, Chervoneva I, et al
    An in vivo reporter to quantitatively and temporally analyze the effects of CDK4/6 inhibitor-based therapies in melanoma.
    Cancer Res. 2016 Aug 3. pii: canres.3384.2015.
    PubMed     Text format     Abstract available


    June 2016
  14. ORSO F, Quirico L, Virga F, Penna E, et al
    miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer.
    Cancer Res. 2016 Jun 21. pii: canres.1322.2015.
    PubMed     Text format     Abstract available


  15. BAKDASH G, Buschow SI, Gorris M, Halilovic A, et al
    Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines.
    Cancer Res. 2016 Jun 20. pii: canres.1695.2015.
    PubMed     Text format     Abstract available


  16. BOYLE SE, Fedele CG, Corbin V, Wybacz E, et al
    CD271 Expression on Patient Melanoma Cells Is Unstable and Unlinked to Tumorigenicity.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  17. ZHAO F, Sucker A, Horn S, Heeke C, et al
    Melanoma lesions independently acquire T-cell resistance during metastatic latency.
    Cancer Res. 2016 Jun 3. pii: canres.0008.2016.
    PubMed     Text format     Abstract available


  18. SCHWARTZ H, Blacher E, Amer M, Livneh N, et al
    Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation.
    Cancer Res. 2016 Jun 3. pii: canres.0485.2016.
    PubMed     Text format     Abstract available


    May 2016
  19. HARBST K, Lauss M, Cirenajwis H, Isaksson K, et al
    Multi-region whole-exome sequencing uncovers the genetic evolution and mutational heterogeneity of early-stage metastatic melanoma.
    Cancer Res. 2016 May 23. pii: canres.3476.2016.
    PubMed     Text format     Abstract available


  20. LAZAR I, Clement E, Dauvillier S, Milhas D, et al
    Adipocyte exosomes promote melanoma aggressiveness through fatty acid oxidation: a novel mechanism linking obesity and cancer.
    Cancer Res. 2016 May 23. pii: canres.0651.2016.
    PubMed     Text format     Abstract available


  21. YAMADA K, Uchiyama A, Uehara A, Perera B, et al
    MFG-E8 drives melanoma growth by stimulating mesenchymal stromal cell-induced angiogenesis and M2 polarization of tumor-associated macrophages.
    Cancer Res. 2016 May 17. pii: canres.2812.2015.
    PubMed     Text format     Abstract available


  22. HOLLANDER L, Guo X, Velazquez H, Chang J, et al
    Renalase expression by melanoma and tumor associated-macrophages promotes tumor growth through a STAT3-mediated mechanism.
    Cancer Res. 2016 May 9. pii: canres.1524.2015.
    PubMed     Text format     Abstract available


    April 2016
  23. NEVALA WK, Buhrow SA, Knauer DJ, Reid JM, et al
    Antibody Targeted Chemotherapy for the Treatment of Melanoma.
    Cancer Res. 2016 Apr 28. pii: canres.3131.2015.
    PubMed     Text format     Abstract available


  24. WEBER CE, Luo C, Hotz-Wagenblatt A, Gardyan A, et al
    miR-339-3p is a tumor suppressor in melanoma.
    Cancer Res. 2016 Apr 15. pii: canres.2932.2015.
    PubMed     Text format     Abstract available


  25. LIM S, Liu H, Madeira da Silva L, Arora R, et al
    Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1alpha.
    Cancer Res. 2016;76:2231-42.
    PubMed     Text format     Abstract available


  26. VASATURO A, Halilovic A, Bol KF, Verweij DI, et al
    T cell landscape in a primary melanoma predicts the survival of patients with metastatic disease after their treatment with dendritic cell vaccines.
    Cancer Res. 2016 Apr 11. pii: canres.3211.2015.
    PubMed     Text format     Abstract available


    March 2016
  27. HERRERA-ABREU MT, Palafox M, Asghar U, Rivas MA, et al
    Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  28. SHOSHAN E, Braeuer RR, Kamiya T, Mobley AK, et al
    NFAT1 directly regulates IL-8 and MMP-3 to promote melanoma tumor growth and metastasis.
    Cancer Res. 2016 Mar 24. pii: canres.2511.2015.
    PubMed     Text format     Abstract available


  29. YOSHIDA A, Lee EK, Diehl JA
    Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended Inhibition of CDK4/6.
    Cancer Res. 2016 Mar 17. pii: canres.2931.2015.
    PubMed     Text format     Abstract available


  30. BUDINA-KOLOMETS A, Webster MR, Leu JI, Jennis M, et al
    HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors.
    Cancer Res. 2016 Mar 16. pii: canres.2137.2015.
    PubMed     Text format     Abstract available


  31. KRUMM A, Barckhausen C, Kucuk P, Tomaszowski KH, et al
    Enhanced histone deacetylase activity in malignant melanoma provokes RAD51 and FANCD2 triggered drug resistance.
    Cancer Res. 2016 Mar 15. pii: canres.2680.2015.
    PubMed     Text format     Abstract available


  32. NIKOLAI BC, Lanz RB, York B, Dasgupta S, et al
    HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes.
    Cancer Res. 2016;76:1463-75.
    PubMed     Text format     Abstract available


  33. BOUSSEMART L, Girault I, Malka-Mahieu H, Mateus C, et al
    Secondary Tumors Arising in Patients Undergoing BRAF Inhibitor Therapy Exhibit Increased BRAF-CRAF Heterodimerization.
    Cancer Res. 2016;76:1476-84.
    PubMed     Text format     Abstract available


  34. JONES LM, Broz ML, Ranger JJ, Ozcelik J, et al
    STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis.
    Cancer Res. 2016;76:1416-28.
    PubMed     Text format     Abstract available


  35. JOHNSON N, De Ieso P, Migliorini G, Orr N, et al
    Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  36. HUH SJ, Oh H, Peterson MA, Almendro V, et al
    The proliferative activity of mammary epithelial cells in normal tissue predicts breast cancer risk in premenopausal women.
    Cancer Res. 2016 Mar 3. pii: canres.1927.2015.
    PubMed     Text format     Abstract available


  37. NAKANISHI Y, Walter K, Spoerke JM, O'Brien C, et al
    Activating Mutations in PIK3CB Confer Resistance to PI3K Inhibition and Define a Novel Oncogenic Role for p110beta.
    Cancer Res. 2016;76:1193-203.
    PubMed     Text format     Abstract available


    February 2016
  38. LUCENAY KS, Doostan I, Karakas C, Bui T, et al
    Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells.
    Cancer Res. 2016 Feb 29. pii: canres.1646.2015.
    PubMed     Text format     Abstract available


  39. NWANI NG, Deguiz ML, Jimenez B, Vinokour E, et al
    Melanoma cells block PEDF production in fibroblasts to induce the tumor-promoting phenotype of cancer-associated fibroblasts.
    Cancer Res. 2016 Feb 26. pii: canres.2468.2015.
    PubMed     Text format     Abstract available


  40. JIANG YZ, Liu YR, Xu XE, Jin X, et al
    Transcriptome analysis of triple-negative breast cancer reveals an integrated mRNA-lncRNA signature with predictive and prognostic value.
    Cancer Res. 2016 Feb 26. pii: canres.3284.2015.
    PubMed     Text format     Abstract available


  41. DEN HOLLANDER P, Rawls K, Tsimelzon A, Shepherd J, et al
    Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival.
    Cancer Res. 2016 Feb 26. pii: canres.0673.2014.
    PubMed     Text format     Abstract available


  42. SAHA S, Mukherjee S, Khan P, Kajal K, et al
    Aspirin suppresses the acquisition of chemo-resistance in breast cancer by disrupting an NFkappaB-IL6 signaling axis responsible for the generation of cancer stem cells.
    Cancer Res. 2016 Feb 3. pii: canres.1360.2015.
    PubMed     Text format     Abstract available


  43. NAKAJIMA K, Kho DH, Yanagawa T, Harazono Y, et al
    Galectin-3 cleavage alters bone remodeling: Different outcomes in breast and prostate cancer skeletal metastasis.
    Cancer Res. 2016 Feb 2. pii: canres.1793.2015.
    PubMed     Text format     Abstract available


  44. LU W, Ning H, Gu L, Peng H, et al
    MCPIP1 selectively destabilizes transcripts associated with an anti-apoptotic gene expression program in breast cancer cells that can elicit complete tumor regression.
    Cancer Res. 2016 Feb 1. pii: canres.1115.2015.
    PubMed     Text format     Abstract available


  45. YOUNGBLOOD VM, Kim LC, Edwards DN, Hwang Y, et al
    The ephrin-A1/EPHA2 signaling axis regulates glutamine metabolism in HER2-positive breast cancer.
    Cancer Res. 2016 Feb 1. pii: canres.0847.2015.
    PubMed     Text format     Abstract available


    January 2016
  46. REGAN ANDERSON TM, Ma SH, Raj GV, Cidlowski JA, et al
    Breast Tumor Kinase (Brk/PTK6) is Induced by HIF, Glucocorticoid Receptor and PELP1 Mediated Stress Signaling in Triple-Negative Breast Cancer.
    Cancer Res. 2016 Jan 29. pii: canres.2510.2015.
    PubMed     Text format     Abstract available


  47. ZHAO W, Prijic S, Urban BC, Tisza MJ, et al
    Candidate anti-metastasis drugs suppress the metastatic capacity of breast cancer cells by reducing membrane fluidity.
    Cancer Res. 2016 Jan 29. pii: canres.1970.2015.
    PubMed     Text format     Abstract available


  48. BONYADI RAD E, Hammerlindl H, Wels C, Popper U, et al
    Notch4 signaling induces a mesenchymal-epithelial-like transition in melanoma cells to suppress malignant behaviors.
    Cancer Res. 2016 Jan 22. pii: canres.1722.2015.
    PubMed     Text format     Abstract available


  49. BACCI M, Giannoni E, Fearns A, Ribas R, et al
    miR-155 drives metabolic reprogramming of ER+ breast cancer cells following long-term estrogen deprivation and predicts clinical response to aromatase inhibitors.
    Cancer Res. 2016 Jan 21. pii: canres.2038.2015.
    PubMed     Text format     Abstract available


  50. CAMP NJ, Lin WY, Bigelow A, Burghel GJ, et al
    Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus.
    Cancer Res. 2016 Jan 21. pii: canres.1629.2015.
    PubMed     Text format     Abstract available


  51. MERINO VF, Nguyen N, Jin K, Sadik H, et al
    Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer.
    Cancer Res. 2016 Jan 19. pii: canres.1619.2015.
    PubMed     Text format     Abstract available


  52. COX TR, Gartland A, Erler JT
    Lysyl Oxidase, a Targetable Secreted Molecule Involved in Cancer Metastasis.
    Cancer Res. 2016;76:188-92.
    PubMed     Text format     Abstract available


  53. TANAKA M, Shimamura S, Kuriyama S, Maeda D, et al
    SKAP2 Promotes Podosome Formation to Facilitate Tumor-Associated Macrophage Infiltration and Metastatic Progression.
    Cancer Res. 2016;76:358-69.
    PubMed     Text format     Abstract available


  54. LIM SO, Li CW, Xia W, Lee HH, et al
    EGFR signaling enhances aerobic glycolysis in triple negative breast cancer cells to promote tumor growth and immune escape.
    Cancer Res. 2016 Jan 12. pii: canres.2478.2015.
    PubMed     Text format     Abstract available


  55. LI CW, Xia W, Lim SO, Hsu JL, et al
    AKT1 inhibits epithelial-to-mesenchymal transition in breast cancer through phosphorylation-dependent Twist1 degradation.
    Cancer Res. 2016 Jan 12. pii: canres.1941.2015.
    PubMed     Text format     Abstract available


  56. ESPELIN CW, Leonard SC, Geretti E, Wickham TJ, et al
    Dual HER2 targeting with trastuzumab and liposome-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancer.
    Cancer Res. 2016 Jan 12. pii: canres.1518.2015.
    PubMed     Text format     Abstract available


  57. WEBER C, Telerman SB, Reimer AS, Sequeira I, et al
    Macrophage infiltration and alternative activation during wound healing promote MEK1-induced skin carcinogenesis.
    Cancer Res. 2016 Jan 11. pii: canres.3676.2014.
    PubMed     Text format     Abstract available


  58. JIANG L, Yu L, Zhang X, Lei F, et al
    miR-892b silencing activates NF-kappaB and promotes aggressiveness in breast cancer.
    Cancer Res. 2016 Jan 8. pii: canres.1770.2015.
    PubMed     Text format     Abstract available


  59. VINERETSKY KA, Karagas MR, Christensen BC, Kuriger-Laber JK, et al
    Skin Cancer Risk Is Modified by KIR/HLA Interactions That Influence the Activation of Natural Killer Immune Cells.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  60. MITTAL D, Caramia F, Michiels S, Joensuu H, et al
    Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  61. PICON-RUIZ M, Pan C, Drews-Elger K, Jang K, et al
    Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression.
    Cancer Res. 2016.
    PubMed     Text format     Abstract available


  62. PARK WY, Hong BJ, Lee J, Choi C, et al
    H3K27 Demethylase JMJD3 Employs the NF-kappaB and BMP Signaling Pathways to Modulate the Tumor Microenvironment and Promote Melanoma Progression and Metastasis.
    Cancer Res. 2016;76:161-70.
    PubMed     Text format     Abstract available


  63. JIANG Y, Pan Y, Rhea PR, Tan L, et al
    A Sucrose-Enriched Diet Promotes Tumorigenesis in Mammary Gland in Part through the 12-Lipoxygenase Pathway.
    Cancer Res. 2016;76:24-9.
    PubMed     Text format     Abstract available


    December 2015
  64. DA SILVA-DIZ V, Simon-Extremera P, Bernat-Peguera A, de Sostoa J, et al
    Cancer stem cell regulation changes at late stages of skin carcinoma progression to enhance tumor growth and metastasis.
    Cancer Res. 2015 Dec 30. pii: canres.1631.2015.
    PubMed     Text format     Abstract available


  65. ZIMMERMAN EI, Gibson AA, Hu S, Vasilyeva A, et al
    Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  66. MITTAPALLI VR, Madl J, Loffek S, Kiritsi D, et al
    Injury-driven Stiffening of the Dermis Expedites Skin Carcinoma Progression.
    Cancer Res. 2015 Dec 16. pii: canres.1348.2015.
    PubMed     Text format     Abstract available


  67. BHOLA NE, Jansen VM, Koch JP, Li H, et al
    Treatment of Triple Negative Breast Cancer With TORC1/2 Inhibitors Sustains a Drug-resistant and Notch-dependent Cancer Stem Cell Population.
    Cancer Res. 2015 Dec 16. pii: canres.1640.2015.
    PubMed     Text format     Abstract available


  68. JIANG H, Sun HF, Gao SP, Li LD, et al
    SSBP1 Suppresses TGF-beta-Driven Epithelial-to-Mesenchymal Transition and Metastasis in Triple-Negative Breast Cancer by Regulating Mitochondrial Retrograde Signaling.
    Cancer Res. 2015 Dec 16. pii: canres.1630.2015.
    PubMed     Text format     Abstract available


  69. ADAMS BD, Wali VB, Cheng CJ, Inukai S, et al
    miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple Negative Breast Cancer.
    Cancer Res. 2015 Dec 16. pii: canres.2321.2015.
    PubMed     Text format     Abstract available


  70. KOGUCHI Y, Hoen HM, Bambina SA, Rynning MD, et al
    Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
    Cancer Res. 2015;75:5084-92.
    PubMed     Text format     Abstract available


  71. RANJAN A, Gupta P, Srivastava SK
    Penfluridol: An antipsychotic agent suppresses metastatic tumor growth in triple negative breast cancer by inhibiting integrin signaling axis.
    Cancer Res. 2015 Dec 1. pii: canres.1233.2015.
    PubMed     Text format     Abstract available


    November 2015
  72. FENG Y, Pinkerton AB, Hulea L, Zhang T, et al
    SBI-0640756 Attenuates the Growth of Clinically Unresponsive Melanomas by Disrupting the eIF4F Translation Initiation Complex.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  73. YUZEFOVYCH LV, Kahn AG, Schuler MA, Eide L, et al
    Mitochondrial DNA repair through OGG1 activity attenuates breast cancer progression and metastasis.
    Cancer Res. 2015 Nov 19. pii: canres.0692.2015.
    PubMed     Text format     Abstract available


  74. HERKERT B, Kauffmann A, Molle S, Schnell C, et al
    Maximizing the efficacy of MAPK-targeted treatment in PTENLOF/BRAFMUT melanoma through PI3K and IGF1R inhibition.
    Cancer Res. 2015 Nov 17. pii: canres.3358.2014.
    PubMed     Text format     Abstract available


  75. BARTKOWIAK K, Kwiatkowski M, Buck F, Gorges TM, et al
    Disseminated tumor cells persist in the bone marrow of breast cancer patients through sustained activation of the unfolded protein response.
    Cancer Res. 2015 Nov 16. pii: canres.3728.2014.
    PubMed     Text format     Abstract available


  76. LANZARDO S, Conti L, Rooke R, Ruiu R, et al
    Immunotargeting of antigen xCT attenuates stem-like cell behavior and metastatic progression in breast cancer.
    Cancer Res. 2015 Nov 13. pii: canres.1208.2015.
    PubMed     Text format     Abstract available


  77. JOSEFSSON A, Nedrow JR, Park S, Ray Banerjee S, et al
    Imaging, biodistribution, and dosimetry of radionuclide-labeled PD-L1 antibody in an immunocompetent mouse model of breast cancer.
    Cancer Res. 2015 Nov 10. pii: canres.2141.2015.
    PubMed     Text format     Abstract available


  78. ROLFS F, Huber M, Kuehne A, Kramer S, et al
    Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  79. MAZZIERI R, Pietrogrande G, Gerasi L, Gandelli A, et al
    Urokinase Receptor Promotes Skin Tumor Formation by Preventing Epithelial Cell Activation of Notch1.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  80. PETERSON EA, Jenkins EC, Lofgren KA, Chandiramani N, et al
    Amphiregulin Is a Critical Downstream Effector of Estrogen Signaling in ERalpha-Positive Breast Cancer.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


    October 2015
  81. HOLZEL M, Landsberg J, Glodde N, Bald T, et al
    A preclinical model of malignant peripheral nerve sheath tumor-like melanoma is characterized by infiltrating mast cells.
    Cancer Res. 2015 Oct 28. pii: canres.1090.2015.
    PubMed     Text format     Abstract available


  82. FEELEY KP, Bray AW, Westbrook DG, Johnson LW, et al
    Mitochondrial Genetics Regulate Breast Cancer Tumorigenicity and Metastatic Potential.
    Cancer Res. 2015;75:4429-36.
    PubMed     Text format     Abstract available


  83. LEGARE S, Cavallone L, Mamo A, Chabot C, et al
    The Estrogen Receptor Cofactor SPEN Functions as a Tumor Suppressor and Candidate Biomarker of Drug Responsiveness in Hormone-Dependent Breast Cancers.
    Cancer Res. 2015;75:4351-63.
    PubMed     Text format     Abstract available


  84. AO Z, Shah SH, Machlin LM, Parajuli R, et al
    Identification of cancer associated fibroblasts in circulating blood from patients with metastatic breast cancer.
    Cancer Res. 2015 Oct 15. pii: canres.1633.2015.
    PubMed     Text format     Abstract available


  85. WIJDEVEN RH, Pang B, van der Zanden SY, Qiao X, et al
    Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
    Cancer Res. 2015;75:4176-87.
    PubMed     Text format     Abstract available


  86. FRANKENBERGER C, Rabe D, Bainer R, Sankarasharma D, et al
    Metastasis Suppressors Regulate the Tumor Microenvironment by Blocking Recruitment of Prometastatic Tumor-Associated Macrophages.
    Cancer Res. 2015;75:4063-73.
    PubMed     Text format     Abstract available


  87. PUNDIR S, Vu HY, Solomon VR, McClure R, et al
    VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
    Cancer Res. 2015;75:4164-75.
    PubMed     Text format     Abstract available


    September 2015
  88. WRIGHT KL, Adams JR, Liu JC, Loch AJ, et al
    Ras signaling is a key determinant of metastatic dissemination and poor survival of luminal breast cancer patients.
    Cancer Res. 2015 Sep 23. pii: canres.2992.2014.
    PubMed     Text format     Abstract available


  89. MAZIVEYI M, Alahari SK
    Breast Cancer Tumor Suppressors: A Special Emphasis on Novel Protein Nischarin.
    Cancer Res. 2015.
    PubMed     Text format     Abstract available


  90. JAIN S, Wang X, Chang CC, Ibarra-Drendall C, et al
    Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
    Cancer Res. 2015 Sep 17. pii: canres.2345.2014.
    PubMed     Text format     Abstract available


  91. ERICKSON-BHATT SJ, Nolan RM, Shemonski ND, Adie SG, et al
    Real-time Imaging of the Resection Bed Using a Handheld Probe to Reduce Incidence of Microscopic Positive Margins in Cancer Surgery.
    Cancer Res. 2015;75:3706-12.
    PubMed     Text format     Abstract available


  92. ZHONG R, Bao R, Faber PW, Bindokas VP, et al
    Notch1 Activation or Loss Promotes HPV-Induced Oral Tumorigenesis.
    Cancer Res. 2015;75:3958-69.
    PubMed     Text format     Abstract available


  93. WU MZ, Chen SF, Nieh S, Benner C, et al
    Hypoxia Drives Breast Tumor Malignancy through a TET-TNFalpha-p38-MAPK Signaling Axis.
    Cancer Res. 2015;75:3912-24.
    PubMed     Text format     Abstract available


  94. ABBA MC, Gong T, Lu Y, Lee J, et al
    A Molecular Portrait of High-Grade Ductal Carcinoma In Situ.
    Cancer Res. 2015;75:3980-90.
    PubMed     Text format     Abstract available


  95. HARMS PW, Vats P, Verhaegen ME, Robinson DR, et al
    The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma.
    Cancer Res. 2015;75:3720-7.
    PubMed     Text format     Abstract available


  96. JACOB LS, Vanharanta S, Obenauf AC, Pirun M, et al
    Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations.
    Cancer Res. 2015;75:3713-9.
    PubMed     Text format     Abstract available


  97. BENEVIDES L, da Fonseca DM, Donate PB, Tiezzi DG, et al
    IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment.
    Cancer Res. 2015;75:3788-99.
    PubMed     Text format     Abstract available


  98. D'AMATO NC, Rogers TJ, Gordon MA, Greene LI, et al
    A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer.
    Cancer Res. 2015 Sep 11. pii: canres.2011.2015.
    PubMed     Text format     Abstract available


  99. ZHAN QM, Chen J, Lan T, Zhang W, et al
    Feed forward reciprocal activation of PAFR and STAT3 regulates epithelial-mesenchymal transition in non-small cell lung cancer.
    Cancer Res. 2015 Sep 10. pii: canres.1062.2015.
    PubMed     Text format     Abstract available


  100. YOO B, Kavishwar A, Ross A, Wang P, et al
    Combining miR10b-targeted nanotherapy with low-dose doxorubicin elicits durable regressions of metastatic breast cancer.
    Cancer Res. 2015 Sep 10. pii: canres.0888.2015.
    PubMed     Text format     Abstract available


  101. O'BRIEN SK, Chen L, Zhong W, Armellino D, et al
    Breast cancer cells respond differentially to modulation of TGF-beta2 signaling after exposure to chemotherapy or hypoxia.
    Cancer Res. 2015 Sep 4. pii: canres.0650.2015.
    PubMed     Text format     Abstract available


  102. WEIS JA, Miga MI, Arlinghaus LR, Li X, et al
    Predicting the Response of Breast Cancer to Neoadjuvant Therapy Using a Mechanically Coupled Reaction-Diffusion Model.
    Cancer Res. 2015 Sep 2. pii: canres.2945.2014.
    PubMed     Text format     Abstract available


  103. HUGHES R, Qian BZ, Rowan C, Muthana M, et al
    Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy.
    Cancer Res. 2015;75:3479-91.
    PubMed     Text format     Abstract available


  104. JI W, Li Y, He Y, Yin M, et al
    AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis.
    Cancer Res. 2015;75:3492-504.
    PubMed     Text format     Abstract available


    August 2015
  105. DANG TT, Esparza MA, Maine EA, Westcott JM, et al
    DeltaNp63alpha promotes breast cancer cell motility through the selective activation of components of the epithelial-to-mesenchymal transition program.
    Cancer Res. 2015 Aug 19. pii: canres.3363.2014.
    PubMed     Text format     Abstract available


  106. HULTBERG A, Morello V, Huyghe L, De Jonge N, et al
    Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.
    Cancer Res. 2015;75:3373-83.
    PubMed     Text format     Abstract available


  107. KENNEDY BF, McLaughlin RA, Kennedy KM, Chin L, et al
    Investigation of Optical Coherence Microelastography as a Method to Visualize Cancers in Human Breast Tissue.
    Cancer Res. 2015;75:3236-45.
    PubMed     Text format     Abstract available


  108. ZHANG Q, Qin J, Zhong L, Gong L, et al
    CCL5-mediated Th2 immune polarization promotes metastasis in luminal breast cancer.
    Cancer Res. 2015 Aug 6. pii: canres.3590.2014.
    PubMed     Text format     Abstract available


    July 2015
  109. LIANG Y, Hu J, Li J, Liu Y, et al
    Epigenetic Activation of TWIST1 by MTDH Promotes Cancer Stem-Like Cell Traits in Breast Cancer.
    Cancer Res. 2015 Jul 3. pii: canres.0930.2015.
    PubMed     Text format     Abstract available


    June 2015
  110. KATAYAMA H, Boldt C, Ladd JJ, Johnson MM, et al
    An autoimmune response signature associated with the development of triple negative breast cancer reflects disease pathogenesis.
    Cancer Res. 2015 Jun 18. pii: canres.0248.2015.
    PubMed     Text format     Abstract available


  111. LI XQ, Du X, Li DM, Kong PZ, et al
    ITGBL1 is a Runx2 Transcriptional Target and Promotes Breast Cancer Bone Metastasis by Activating the TGF-beta Signaling Pathway.
    Cancer Res. 2015 Jun 9. pii: canres.0240.2015.
    PubMed     Text format     Abstract available


    April 2015
  112. BUSCH S, Sims AH, Stal O, Ferno M, et al
    Loss of TGFbeta Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
    Cancer Res. 2015;75:1457-69.
    PubMed     Text format     Abstract available


  113. BROWN M, Chinnaiyan A, Farsetti A, Livingston DM, et al
    26th Pezcoller symposium: cancers driven by hormones.
    Cancer Res. 2015;75:1177-80.
    PubMed     Text format     Abstract available


  114. FOX JL, Storey A
    BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs.
    Cancer Res. 2015;75:1345-55.
    PubMed     Text format     Abstract available


    February 2015
  115. YOSHIDA T, Kim JH, Carver K, Su Y, et al
    CLK2 is an oncogenic kinase and splicing regulator in breast cancer.
    Cancer Res. 2015 Feb 10. pii: canres.2443.2014.
    PubMed     Text format     Abstract available


  116. YE FG, Song C, Cao ZG, Xia C, et al
    Cytidine deaminase axis modulated by miR-484 differentially regulates cell proliferation and chemoresistance in breast cancer.
    Cancer Res. 2015 Feb 2. pii: canres.2341.2014.
    PubMed     Text format     Abstract available


    January 2015
  117. TAIPALEENMAKI H, Browne G, Akech J, Zustin J, et al
    Targeting of Runx2 by miRNA-135 and miRNA-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease.
    Cancer Res. 2015 Jan 29. pii: canres.1026.2014.
    PubMed     Text format     Abstract available


  118. YU L, Liu X, Cui K, Di Y, et al
    SND1 acts downstream of TGFbeta1 and upstream of Smurf1 to promote breast cancer metastasis.
    Cancer Res. 2015 Jan 16. pii: canres.2387.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: